Whileour current study is focused on the directed evolution ofnanoscale, decent PD-L1 binders and their application in CD19-SynNotchPDbody-CAR T cells, we are enthusiastic about the prospect of futureresearch that delves into the integration of nanodelivery technologies.Specifically, we can foresee the future integration of nanoparticlesfor the tumor-specific delivery of antigens,67,68 or in vivo genetic manipulation of CAR-T cells69−71 would further achieve better T cell control, improve T cell function,and enhance the tumor elimination efficacy of our CD19-SynNotch PDbody-CART cells. The gene discussed is CD19; the disease is neoplasm.